Pulmosmart G Pulmicaps is a specialized pharmaceutical formulation designed to address the complexities of chronic obstructive pulmonary disease (COPD). This innovative product combines three active ingredients: budesonide, formoterol, and glycopyrronium, each playing a crucial role in managing airway dysfunction. Budesonide, a corticosteroid, works by reducing inflammation in the airways, effectively suppressing the immune response that leads to chronic inflammation. This action helps to decrease mucus production and swelling in the airways, making breathing easier for patients suffering from COPD. Formoterol, a long-acting beta-2 adrenergic agonist (LABA), acts on specific receptors in the smooth muscles of the airways, promoting relaxation and widening of the bronchial tubes. This bronchodilation effect is essential for improving airflow and alleviating symptoms associated with COPD. Glycopyrronium, classified as a long-acting muscarinic antagonist (LAMA), complements the actions of budesonide and formoterol by blocking muscarinic receptors in the airway smooth muscle. This blockade prevents acetylcholine from causing constriction, further enhancing airway relaxation. The combination of these three medications in Pulmosmart G Pulmicaps provides a comprehensive approach to managing COPD, particularly for patients who do not achieve adequate control with dual therapy alone. As a maintenance medication, Pulmosmart G Pulmicaps is intended for regular use to maintain optimal lung function and reduce the frequency of exacerbations. It is important to note that sudden discontinuation of Pulmosmart G Pulmicaps after prolonged use should be avoided to prevent worsening of symptoms. The safety and efficacy of this medication have not been established for children, thus it should not be administered to pediatric patients without consulting a healthcare professional. Overall, Pulmosmart G Pulmicaps represents a significant advancement in the management of COPD, offering patients a reliable option for long-term control of their respiratory condition.
Uses & Benefits
Pulmosmart G Pulmicaps combines three distinct medications: budesonide, formoterol, and glycopyrronium for effective COPD management.
This formulation lowers the frequency of moderate to severe COPD flare-ups compared to dual therapies.
Pulmosmart G Pulmicaps provides double bronchodilation through LABA and LAMA mechanisms, resulting in enhanced airway widening.
Improves lung function as measured by FEV1 and peak expiratory flow metrics.
Reduces reliance on short-acting rescue inhalers when used consistently as a maintenance therapy.
Clinical trials indicate that patients using Pulmosmart G Pulmicaps have a lower risk of mortality compared to those on dual therapy alone.
Effective for individuals with chronic bronchitis and emphysema as part of their COPD treatment plan.
Pulmosmart G Pulmicaps is recommended for patients who experience inadequate symptom control with other medications.
How Pulmosmart G Pulmicaps works
Pulmosmart G Pulmicaps utilizes a synergistic mechanism involving its three active components to effectively manage COPD symptoms. The combination of budesonide, formoterol, and glycopyrronium works together to enhance airway function and reduce inflammation.
Budesonide binds to glucocorticoid receptors within cells, inhibiting pro-inflammatory gene expression and reducing immune cell activity.
Formoterol stimulates beta-2 adrenergic receptors on airway smooth muscle, leading to relaxation and dilation of bronchial passages.
The combined action of these three agents results in improved airflow and reduced respiratory distress in COPD patients.
Pulmosmart G Pulmicaps provides rapid relief from symptoms while also addressing underlying inflammation.
This triple-action approach allows for better management of chronic respiratory conditions compared to single or dual therapies.
How to use Pulmosmart G Pulmicaps
Pulmosmart G Pulmicaps should be administered via a metered-dose inhaler (MDI).
Shake the inhaler well before use and exhale fully before inhalation.
Seal your lips around the mouthpiece and inhale deeply while pressing down on the canister.
Hold your breath for 10 seconds after inhalation to allow the medication to settle in your lungs.
Each dose consists of 2 puffs taken twice daily, ideally spaced 12 hours apart.
Always rinse your mouth with water after using Pulmosmart G Pulmicaps to prevent oral infections.
This medication is not intended for immediate relief of acute symptoms; always carry a rescue inhaler for emergencies.
Discard the inhaler when the dose counter indicates zero doses remaining.
Lifestyle Advice
Maintain a consistent daily routine for taking Pulmosmart G Pulmicaps to ensure optimal therapeutic levels are achieved.
Avoid exposure to respiratory irritants such as smoke or strong odors that may exacerbate COPD symptoms.
Incorporate regular physical activity as tolerated; consult your doctor for an appropriate exercise plan.
Stay hydrated to support overall lung function and mucus clearance from the airways.
Monitor your diet; avoid excessive salt intake which can lead to fluid retention and worsen respiratory issues.
Consider using a humidifier at home to maintain moisture in the air, which can help ease breathing difficulties.
Side Effects
Side Effects
Common side effects may include oral candidiasis (fungal infection), hoarseness, headache, cough, and tremors.
Nasal dryness or irritation can occur with the use of Pulmosmart G Pulmicaps.
Palpitations or increased heart rate may be experienced by some patients.
Uncommon side effects include low potassium levels (hypokalemia), increased blood pressure, and sleep disturbances.
Serious side effects requiring immediate medical attention include paradoxical bronchospasm and severe adrenal insufficiency.
Patients should monitor for signs of severe allergic reactions such as angioedema or cardiovascular issues like chest pain.
Consult a healthcare provider if any severe side effects occur or if symptoms worsen after using Pulmosmart G Pulmicaps.
Precautions and Warnings
Precautions & Warnings
Pulmosmart G Pulmicaps should not be used by individuals with known hypersensitivity to any of its components.
Patients with pre-existing heart conditions should use this medication cautiously due to potential cardiovascular effects.
Consult a doctor before using if pregnant or breastfeeding; safety data is limited for glycopyrronium and formoterol during these periods.
Avoid alcohol consumption as it may irritate the airways and reduce treatment efficacy.
Patients with liver or kidney impairment should seek medical advice before using this medication due to altered drug metabolism and clearance.
Regular monitoring is advised for patients with diabetes as budesonide may elevate blood glucose levels.
Do not discontinue use abruptly; consult your healthcare provider for a tapering plan if necessary.
1. What is the primary use of Pulmosmart G Pulmicaps?
Pulmosmart G Pulmicaps is primarily used for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.
2. Can I take Pulmosmart G Pulmicaps after meals?
Yes, you can take Pulmosmart G Pulmicaps before or after meals as meal timing does not affect its effectiveness.
3. Is it safe to use Pulmosmart G Pulmicaps if I have diabetes?
While it can be used by diabetic patients, caution is advised as budesonide may raise blood glucose levels. Regular monitoring is recommended.
4. Can I combine Pulmosmart G Pulmicaps with antibiotics?
Certain antibiotics may interact with budesonide; always inform your doctor about all medications you are taking before starting treatment.
5. Is Pulmosmart G Pulmicaps suitable for children?
No, the safety and efficacy of Pulmosmart G Pulmicaps have not been established in children.
6. What should I do if I miss a dose of Pulmosmart G Pulmicaps?
If you miss a dose, take it as soon as you remember. If it's almost time for your next dose, skip the missed dose and continue with your regular schedule.
7. Can I stop taking Pulmosmart G Pulmicaps suddenly?
No, stopping suddenly can lead to worsening symptoms. Consult your doctor for guidance on how to taper off safely.
Directions for Use
Use only as prescribed by your physician.
Storage and Disposal
Please refer to the product label for storage information.
SKU
406180
Country of Manufacture
India
Manufacturer Address
Alkem Laboratories Limited
Return/Buy Back policy
Non-returnable
Prescription Required
Yes
Storage
Please refer to the product label for storage information.
Seller
Kogland Commerce Pvt Ltd (TN)
Pulmosmart G Pulmicaps is a specialized pharmaceutical formulation designed to address the complexities of chronic obstructive pulmonary disease (COPD). This innovative product combines three active ingredients: budesonide, formoterol, and glycopyrronium, each playing a crucial role in managing airway dysfunction. Budesonide, a corticosteroid, works by reducing inflammation in the airways, effectively suppressing the immune response that leads to chronic inflammation. This action helps to decrease mucus production and swelling in the airways, making breathing easier for patients suffering from COPD. Formoterol, a long-acting beta-2 adrenergic agonist (LABA), acts on specific receptors in the smooth muscles of the airways, promoting relaxation and widening of the bronchial tubes. This bronchodilation effect is essential for improving airflow and alleviating symptoms associated with COPD. Glycopyrronium, classified as a long-acting muscarinic antagonist (LAMA), complements the actions of budesonide and formoterol by blocking muscarinic receptors in the airway smooth muscle. This blockade prevents acetylcholine from causing constriction, further enhancing airway relaxation. The combination of these three medications in Pulmosmart G Pulmicaps provides a comprehensive approach to managing COPD, particularly for patients who do not achieve adequate control with dual therapy alone. As a maintenance medication, Pulmosmart G Pulmicaps is intended for regular use to maintain optimal lung function and reduce the frequency of exacerbations. It is important to note that sudden discontinuation of Pulmosmart G Pulmicaps after prolonged use should be avoided to prevent worsening of symptoms. The safety and efficacy of this medication have not been established for children, thus it should not be administered to pediatric patients without consulting a healthcare professional. Overall, Pulmosmart G Pulmicaps represents a significant advancement in the management of COPD, offering patients a reliable option for long-term control of their respiratory condition.
Uses & Benefits
Pulmosmart G Pulmicaps combines three distinct medications: budesonide, formoterol, and glycopyrronium for effective COPD management.
This formulation lowers the frequency of moderate to severe COPD flare-ups compared to dual therapies.
Pulmosmart G Pulmicaps provides double bronchodilation through LABA and LAMA mechanisms, resulting in enhanced airway widening.
Improves lung function as measured by FEV1 and peak expiratory flow metrics.
Reduces reliance on short-acting rescue inhalers when used consistently as a maintenance therapy.
Clinical trials indicate that patients using Pulmosmart G Pulmicaps have a lower risk of mortality compared to those on dual therapy alone.
Effective for individuals with chronic bronchitis and emphysema as part of their COPD treatment plan.
Pulmosmart G Pulmicaps is recommended for patients who experience inadequate symptom control with other medications.
How Pulmosmart G Pulmicaps works
Pulmosmart G Pulmicaps utilizes a synergistic mechanism involving its three active components to effectively manage COPD symptoms. The combination of budesonide, formoterol, and glycopyrronium works together to enhance airway function and reduce inflammation.
Budesonide binds to glucocorticoid receptors within cells, inhibiting pro-inflammatory gene expression and reducing immune cell activity.
Formoterol stimulates beta-2 adrenergic receptors on airway smooth muscle, leading to relaxation and dilation of bronchial passages.
The combined action of these three agents results in improved airflow and reduced respiratory distress in COPD patients.
Pulmosmart G Pulmicaps provides rapid relief from symptoms while also addressing underlying inflammation.
This triple-action approach allows for better management of chronic respiratory conditions compared to single or dual therapies.
How to use Pulmosmart G Pulmicaps
Pulmosmart G Pulmicaps should be administered via a metered-dose inhaler (MDI).
Shake the inhaler well before use and exhale fully before inhalation.
Seal your lips around the mouthpiece and inhale deeply while pressing down on the canister.
Hold your breath for 10 seconds after inhalation to allow the medication to settle in your lungs.
Each dose consists of 2 puffs taken twice daily, ideally spaced 12 hours apart.
Always rinse your mouth with water after using Pulmosmart G Pulmicaps to prevent oral infections.
This medication is not intended for immediate relief of acute symptoms; always carry a rescue inhaler for emergencies.
Discard the inhaler when the dose counter indicates zero doses remaining.
Lifestyle Advice
Maintain a consistent daily routine for taking Pulmosmart G Pulmicaps to ensure optimal therapeutic levels are achieved.
Avoid exposure to respiratory irritants such as smoke or strong odors that may exacerbate COPD symptoms.
Incorporate regular physical activity as tolerated; consult your doctor for an appropriate exercise plan.
Stay hydrated to support overall lung function and mucus clearance from the airways.
Monitor your diet; avoid excessive salt intake which can lead to fluid retention and worsen respiratory issues.
Consider using a humidifier at home to maintain moisture in the air, which can help ease breathing difficulties.
Side Effects
Side Effects
Common side effects may include oral candidiasis (fungal infection), hoarseness, headache, cough, and tremors.
Nasal dryness or irritation can occur with the use of Pulmosmart G Pulmicaps.
Palpitations or increased heart rate may be experienced by some patients.
Uncommon side effects include low potassium levels (hypokalemia), increased blood pressure, and sleep disturbances.
Serious side effects requiring immediate medical attention include paradoxical bronchospasm and severe adrenal insufficiency.
Patients should monitor for signs of severe allergic reactions such as angioedema or cardiovascular issues like chest pain.
Consult a healthcare provider if any severe side effects occur or if symptoms worsen after using Pulmosmart G Pulmicaps.
Precautions and Warnings
Precautions & Warnings
Pulmosmart G Pulmicaps should not be used by individuals with known hypersensitivity to any of its components.
Patients with pre-existing heart conditions should use this medication cautiously due to potential cardiovascular effects.
Consult a doctor before using if pregnant or breastfeeding; safety data is limited for glycopyrronium and formoterol during these periods.
Avoid alcohol consumption as it may irritate the airways and reduce treatment efficacy.
Patients with liver or kidney impairment should seek medical advice before using this medication due to altered drug metabolism and clearance.
Regular monitoring is advised for patients with diabetes as budesonide may elevate blood glucose levels.
Do not discontinue use abruptly; consult your healthcare provider for a tapering plan if necessary.
1. What is the primary use of Pulmosmart G Pulmicaps?
Pulmosmart G Pulmicaps is primarily used for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.
2. Can I take Pulmosmart G Pulmicaps after meals?
Yes, you can take Pulmosmart G Pulmicaps before or after meals as meal timing does not affect its effectiveness.
3. Is it safe to use Pulmosmart G Pulmicaps if I have diabetes?
While it can be used by diabetic patients, caution is advised as budesonide may raise blood glucose levels. Regular monitoring is recommended.
4. Can I combine Pulmosmart G Pulmicaps with antibiotics?
Certain antibiotics may interact with budesonide; always inform your doctor about all medications you are taking before starting treatment.
5. Is Pulmosmart G Pulmicaps suitable for children?
No, the safety and efficacy of Pulmosmart G Pulmicaps have not been established in children.
6. What should I do if I miss a dose of Pulmosmart G Pulmicaps?
If you miss a dose, take it as soon as you remember. If it's almost time for your next dose, skip the missed dose and continue with your regular schedule.
7. Can I stop taking Pulmosmart G Pulmicaps suddenly?
No, stopping suddenly can lead to worsening symptoms. Consult your doctor for guidance on how to taper off safely.
Directions for Use
Use only as prescribed by your physician.
Storage and Disposal
Please refer to the product label for storage information.
SKU
406180
Country of Manufacture
India
Manufacturer Address
Alkem Laboratories Limited
Return/Buy Back policy
Non-returnable
Prescription Required
Yes
Storage
Please refer to the product label for storage information.
Seller
Kogland Commerce Pvt Ltd (TN)
Door Step Delivery
Quick and Secure
No Hidden Charges
Pay only what's shown
18K Pincodes Served
With Trust & Reliability
Related Products
Customer Reviews
No reviews yet
Be the first to share your thoughts. Honest feedback helps other shoppers and us serve you better.
